A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
Lentiviral vectors are an ideal choice for delivering gene-editing components to cells due to their capacity for stably transducing a broad range of cells and mediating high levels of gene expression. However, their ability to integrate into the host cell genome enhances the risk of insertional mutagenicity and thus raises safety concerns and limits their usage in clinical settings. Further, the persistent expression of gene-editing components delivered by these integration-competent lentiviral vectors (ICLVs) increases the probability of promiscuous gene targeting. As an alternative, a new generation of integrase-deficient lentiviral vectors (IDLVs) has been developed that addresses many of these concerns. Here the production protocol of a new and improved IDLV platform for CRISPR-mediated gene editing and list the steps involved in the purification and concentration of such vectors is described and their transduction and gene-editing efficiency using HEK-293T cells was demonstrated. This protocol is easily scalable and can be used to generate high titer IDLVs that are capable of transducing cells in vitro and in vivo. Moreover, this protocol can be easily adapted for the production of ICLVs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, conventional lentiviral systems integrate into the host genome, posing risks of insertional mutagenesis and limiting their clinical applicability [8].”
From Rapid and Robust Generation of Homozygous Fluorescent Reporter Knock-In Cell Pools by CRISPR-Cas9 (2025) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Unexpected mutations after CRISPR–Cas9 editing in vivo
Schaefer, K. A., Wu, W.-H., Colgan, D. F., Tsang, S. H., Bassuk, A. G., & Mahajan, V. B. (2017) · Nature Methods · doi:10.1038/nmeth.4293 · Cited by 286
RetractedGenome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
CRISPR/Cas, the Immune System of Bacteria and Archaea
Horvath, P., & Barrangou, R. (2010) · Science · doi:10.1126/science.1179555 · Cited by 2,465
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2808 · Cited by 1,993
Kim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
Pattanayak, V., Lin, S., Guilinger, J. P., Ma, E., Doudna, J. A., & Liu, D. R. (2013) · Nature Biotechnology · doi:10.1038/nbt.2673 · Cited by 1,487
Editing DNA Methylation in the Mammalian Genome
Liu, X. S., Wu, H., Ji, X., Stelzer, Y., Wu, X., Czauderna, S., Shu, J., Dadon, D., Young, R. A., & Jaenisch, R. (2016) · Cell · doi:10.1016/j.cell.2016.08.056 · Cited by 1,224
A guide to genome engineering with programmable nucleases
Kim, H., & Kim, J.-S. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3686 · Cited by 1,163
CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea
Marraffini, L. A., & Sontheimer, E. J. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2749 · Cited by 919
Development of an intein-mediated split-Cas9 system for gene therapy
Truong, D.-J. J., Kühner, K., Kühn, R., Werfel, S., Engelhardt, S., Wurst, W., & Ortiz, O. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv601 · Cited by 371
Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector
Kabadi, A. M., Ousterout, D. G., Hilton, I. B., & Gersbach, C. A. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku749 · Cited by 370
Xu, L., Yang, H., Gao, Y., Chen, Z., Xie, L., Liu, Y., Liu, Y., Wang, X., Li, H., Lai, W., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.027 · Cited by 244
Kennedy, E. M., Bassit, L. C., Mueller, H., Kornepati, A. V. R., Bogerd, H. P., Nie, T., Chatterjee, P., Javanbakht, H., Schinazi, R. F., & Cullen, B. R. (2015) · Virology · doi:10.1016/j.virol.2014.12.001 · Cited by 209
Wang, W., Ye, C., Liu, J., Zhang, D., Kimata, J. T., & Zhou, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115987 · Cited by 194
Lentivirus pre-packed with Cas9 protein for safer gene editing
Choi, J. G., Dang, Y., Abraham, S., Ma, H., Zhang, J., Guo, H., Cai, Y., Mikkelsen, J. G., Wu, H., Shankar, P., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.27 · Cited by 192
A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape
Lebbink, R. J., de Jong, D. C. M., Wolters, F., Kruse, E. M., van Ham, P. M., Wiertz, E. J. H. J., & Nijhuis, M. (2017) · Scientific Reports · doi:10.1038/srep41968 · Cited by 158
Van Lint, C., Amella, C. A., Emiliani, S., John, M., Jie, T., & Verdin, E. (1997) · Journal of Virology · doi:10.1128/jvi.71.8.6113-6127.1997 · Cited by 149
Ortinski, P. I., O’Donovan, B., Dong, X., & Kantor, B. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.002 · Cited by 146
Self-citationInhibition of HSV-1 Replication by Gene Editing Strategy
Roehm, P. C., Shekarabi, M., Wollebo, H. S., Bellizzi, A., He, L., Salkind, J., & Khalili, K. (2016) · Scientific Reports · doi:10.1038/srep23146 · Cited by 128
Engineering Delivery Vehicles for Genome Editing
Nelson, C. E., & Gersbach, C. A. (2016) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-080615-034711 · Cited by 118
Methods for Gene Transfer to the Central Nervous System
Kantor, B., Bailey, R. M., Wimberly, K., Kalburgi, S. N., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00003-2 · Cited by 109
Self-citationGómez-Gonzalo, M., Carretero, M., Rullas, J., Lara-Pezzi, E., Aramburu, J., Berkhout, B., Alcamı́, J., & López-Cabrera, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103020200 · Cited by 106
Kantor, B., Ma, H., Webster-Cyriaque, J., Monahan, P. E., & Kafri, T. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905859106 · Cited by 98
Self-citationA Large U3 Deletion Causes Increased In Vivo Expression from a Nonintegrating Lentiviral Vector
Bayer, M., Kantor, B., Cockrell, A., Ma, H., Zeithaml, B., Li, X., McCown, T., & Kafri, T. (2008) · Molecular Therapy · doi:10.1038/mt.2008.199 · Cited by 94
Self-citationGenetic Instability of Live, Attenuated Human Immunodeficiency Virus Type 1 Vaccine Strains
Berkhout, B., Verhoef, K., van Wamel, J. L. B., & Back, N. K. T. (1999) · Journal of Virology · doi:10.1128/jvi.73.2.1138-1145.1999 · Cited by 84
Expression of Distinct α Subunits of GABAAReceptor Regulates Inhibitory Synaptic Strength
Ortinski, P. I., Lu, C., Takagaki, K., Fu, Z., & Vicini, S. (2004) · Journal of Neurophysiology · doi:10.1152/jn.00243.2004 · Cited by 82
Van Lint, C., Ghysdael, J., Paras, P., Burny, A., & Verdin, E. (1994) · Journal of Virology · doi:10.1128/jvi.68.4.2632-2648.1994 · Cited by 78
Creating Higher Titer Lentivirus with Caffeine
Ellis, B. L., Potts, P. R., & Porteus, M. H. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.068 · Cited by 74
Kantor, B., Bayer, M., Ma, H., Samulski, J., Li, C., McCown, T., & Kafri, T. (2011) · Molecular Therapy · doi:10.1038/mt.2010.277 · Cited by 56
Self-citationYiu, G., Tieu, E., Nguyen, A. T., Wong, B., & Smit-McBride, Z. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-20296 · Cited by 55
Bellec, J., Bacchetta, M., Losa, D., Anegon, I., Chanson, M., & Nguyen, T. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150812115939 · Cited by 46
Evaluation of Residual Promoter Activity in γ-Retroviral Self-inactivating (SIN) Vectors
Xu, W., Russ, J. L., & Eiden, M. V. (2011) · Molecular Therapy · doi:10.1038/mt.2011.204 · Cited by 33
Kim, Y.-S., Kim, J., Jung, D.-L., Kang, J.-E., Lee, S.-K., Kim, J., Seol, W., Shin, H.-C., Kwon, H. S., Lint, C. M. V., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414136200 · Cited by 23
Jaalouk, D. E., Crosato, M., Brodt, P., & Galipeau, J. (2006) · Virology Journal · doi:10.1186/1743-422x-3-27 · Cited by 21
324. Multiplex CRISPR/Cas9-Based Genome Engineering from a Single Lentiviral Vector
(2014) · Molecular Therapy · doi:10.1016/s1525-0016(16)35337-0 · Cited by 17
Delivery of Genome Editing Reagents to Hematopoietic Stem/Progenitor Cells
Hoban, M. D., Romero, Z. G., Cost, G. J., Mendel, M. C., Holmes, M. C., & Kohn, D. B. (2016) · Current Protocols in Stem Cell Biology · doi:10.1002/9780470151808.sc05b04s36 · Cited by 12
Ma, H., Kafri, T., Webster-Cyriaque, J., et al. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/ters-gf32 · Cited by 3
Cited by
Kantor, B., Tagliafierro, L., Gu, J., Zamora, M. E., Ilich, E., Grenier, C., Huang, Z. Y., Murphy, S., & Chiba-Falek, O. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.08.019 · Cited by 204
Self-citationDong, W., & Kantor, B. (2021) · Viruses · doi:10.3390/v13071288 · Cited by 169
“Indeed, we recently reported that IDLVs demonstrate significantly lower levels of InDel formation and other off-target effects compared to their integrasecompetent counterparts, both in vitro and in vivo [37,39].”
BackgroundSelf-citationViral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets
Taghdiri, M., & Mussolino, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137333 · Cited by 145
“This enhancement has been pivotal in the genome engineering field as it has allowed the efficient delivery of designer nucleases, such as the CRISPR-Cas9 system, in transplantable cells where sustained nuclease expression is generally unwanted due to its potential genotoxicity [53].”
BackgroundAn Improved Protocol for the Production of Lentiviral Vectors
Brown, L. Y., Dong, W., & Kantor, B. (2020) · STAR Protocols · doi:10.1016/j.xpro.2020.100152 · Cited by 70
Self-citationRittiner, J. E., Moncalvo, M., Chiba‐Falek, O., & Kantor, B. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00148 · Cited by 62
“More recently, we established and optimized IDLV vectors as a means for safe and efficient delivery of CRISPR/Cas9 components (Ortinski et al., 2017; Vijayraghavan and Kantor, 2017).”
MethodSelf-citation
Metadata
- Authors
- Vijayraghavan, S., & Kantor, B.
- Affiliations
- Duke University (US)
- ORCID
- Kantor, Boris
- Venue
- Journal of Visualized Experiments
- Publisher
- MyJove Corporation
- Published
- 2017-12-12
- Issue
- 130
- ISSN
- 1940-087X (ISSN-L)
- PMC
- PMC5755554
- OpenAlex
- W2774779218
- Cited by
- 20
- References
- 43
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 1 · 2020: 2 · 2019: 3 · 2018: 1
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Visualized Experiments (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DukeSpace (Duke University) (submittedVersion, cc-by-nc-nd)
- Funders
- University of South Carolina
- Broad Institute
- École Polytechnique Fédérale de Lausanne
- School of Medicine, Duke University
- School of Medicine, University of South Carolina (RDF18080-E202)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- CRISPR/Cas9, gene knockout, lentiviral vector production, vector purification, HEK293T cells, insertional mutagenesis, gene delivery, in vivo transduction, vector titer
- MeSH terms
- Animals, Cell Division, Genetic Vectors, Humans, Lentivirus, Integrases, Mice, Gene Knockout Techniques, HEK293 Cells, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.